Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Eli Lilly And Company ( ($LLY) ) has released its Q3 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its ...

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

BofA raised the firm’s price target on Eli Lilly (LLY) to $950 from $900 and keeps a Buy rating on the shares after the company reported “strong” ...

For the Magnificent 7 group, Q3 earnings are expected to be up 11.5% from the same period last year on 15.4% higher revenues, ...

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

As of 10 AM Eastern Time, the S&P 500 slipped 0.2%, the Dow Jones Industrial Average was up 0.5%, and the Nasdaq Composite ...

Our Bureau, New Delhi Friday, October 31, 2025, 14:15 Hrs [IST] Cipla Ltd has reported a growth of 3.7% in net profit for the quarter ...